title: Tumor necrosis factor antagonists in the treatment of multicentric reticulohistiocytosis: Current clinical evidence.
abstract: Multicentric reticulohistiocytosis (MRH) is a rare and debilitating systemic disorder characterized by cutaneous nodules and destructive polyarthritis. Due to its unknown etiology, the treatment of MRH varies with different rates of success, which causes treatment options to be rather independent and empirical. In the present study, a case of a 48‑year‑old woman with a 12‑month history of polyarthralgia and skin nodules was reported. Biopsy samples, which were obtained from her skin eruption exhibited dermal infiltration with histiocytes and multinucleated giant cells. Immunohistochemical staining indicated positivity for CD68. The patient was diagnosed with MRH and treated with a combination therapy of infliximab, prednisolone and methotrexate. Her symptoms improved markedly within 2 weeks. Following the results of this case study, a systematic review of 17 cases of MRH treated with tumor necrosis factor (TNF) antagonists was performed, and the efficacy of anti‑TNF treatment in MRH was analyzed.
authors.affiliation: Department of Rheumatology and Immunology, Xiangya Hospital, Central South University, Changsha, Hunan 410008, P.R. China.
authors.forename: Hongjun
authors.initials: H
authors.lastname: Zhao
authors.affiliation: Department of Rheumatology and Immunology, Xiangya Hospital, Central South University, Changsha, Hunan 410008, P.R. China.
authors.forename: Chunmei
authors.initials: C
authors.lastname: Wu
authors.affiliation: Department of Rheumatology and Immunology, Xiangya Hospital, Central South University, Changsha, Hunan 410008, P.R. China.
authors.forename: Mengyun
authors.initials: M
authors.lastname: Wu
authors.affiliation: Department of Rheumatology and Immunology, Xiangya Hospital, Central South University, Changsha, Hunan 410008, P.R. China.
authors.forename: Yaou
authors.initials: Y
authors.lastname: Zhou
authors.affiliation: Department of Rheumatology and Immunology, Xiangya Hospital, Central South University, Changsha, Hunan 410008, P.R. China.
authors.forename: Honglin
authors.initials: H
authors.lastname: Zhu
authors.affiliation: Department of Rheumatology and Immunology, Xiangya Hospital, Central South University, Changsha, Hunan 410008, P.R. China.
authors.forename: Yisha
authors.initials: Y
authors.lastname: Li
authors.affiliation: Department of Rheumatology and Immunology, Xiangya Hospital, Central South University, Changsha, Hunan 410008, P.R. China.
authors.forename: Yunhui
authors.initials: Y
authors.lastname: You
authors.affiliation: Department of Rheumatology and Immunology, Xiangya Hospital, Central South University, Changsha, Hunan 410008, P.R. China.
authors.forename: Hui
authors.initials: H
authors.lastname: Luo
authors.affiliation: Department of Gerontology, Xiangya Hospital, Central South University, Changsha, Hunan 410008, P.R. China.
authors.forename: Lijing
authors.initials: L
authors.lastname: Wang
authors.affiliation: Department of Rheumatology and Immunology, Xiangya Hospital, Central South University, Changsha, Hunan 410008, P.R. China.
authors.forename: Xiaoxia
authors.initials: X
authors.lastname: Zuo
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D001168:Arthritis / Q000175:diagnosis / Q000188:drug therapy / Q000209:etiology / Q000378:metabolism; D015415:Biomarkers; D005260:Female; D015614:Histiocytosis / Q000175:diagnosis / Q000188:drug therapy* / Q000209:etiology / Q000378:metabolism*; D006801:Humans; D007150:Immunohistochemistry; D008875:Middle Aged; D012871:Skin Diseases / Q000175:diagnosis / Q000188:drug therapy / Q000209:etiology / Q000378:metabolism; D016896:Treatment Outcome; D000079424:Tumor Necrosis Factor Inhibitors
chemical_list: D000911:Antibodies, Monoclonal; D015415:Biomarkers; D000079424:Tumor Necrosis Factor Inhibitors